Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | SPHK1 | Q9NYA1 | 3/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.39 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL223652 | 1.00 | DRD2 (0.50) | DRD2CYP2C9MAPTALDH1A1MEN1 | |
| SCHEMBL11282229 | 0.99 | DRD2 (0.49) | DRD2CYP2C9MAPTALDH1A1MEN1 | |
| SCHEMBL11279457 | 0.99 | DRD2 (0.49) | DRD2CYP2C9MAPTALDH1A1MEN1 | |
| SCHEMBL11283921 | 0.99 | DRD2 (0.49) | DRD2CYP2C9MAPTALDH1A1MEN1 | |
| SCHEMBL11287630 | 0.99 | DRD2 (0.49) | DRD2CYP2C9MAPTALDH1A1MEN1 | |
| SCHEMBL11283709 | 0.99 | DRD2 (0.49) | DRD2CYP2C9MAPTALDH1A1MEN1 | |
| SCHEMBL10659015 | 0.99 | DRD2 (0.49) | DRD2CYP2C9MAPTALDH1A1MEN1 | |
| SCHEMBL11286368 | 0.99 | DRD2 (0.49) | DRD2CYP2C9MAPTALDH1A1MEN1 | |
| SCHEMBL21321779 | 0.99 | DRD2 (0.49) | DRD2CYP2C9MAPTALDH1A1MEN1 | |
| SCHEMBL11281659 | 0.96 | DRD2 (0.51) | DRD2CYP2C9MAPTALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 110 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113122269-B | Ultraviolet light absorber | 光学转变公司 | 2024-05-28 | — | — | CN | disclosed |
| US-20230287272-A1 | LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DEVICE | DIC CORPORATION (JP) | 2023-09-14 | — | — | US | disclosed |
| US-11739270-B2 | Polymerizable compound as well as liquid crystal composition and liquid crystal display device each including polymerizable compound | DIC CORPORATION (JP) | 2023-08-29 | — | — | US | disclosed |
| EP-3071576-B1 | PHOTOCHROMIC INDENO-FUSED RING PYRAN COMPOUNDS | TRANSITIONS OPTICAL INC (US) | 2021-08-18 | — | — | EP | disclosed |
| CN-113122269-A | Ultraviolet light absorber | 光学转变公司 | 2021-07-16 | — | — | CN | disclosed |
| CN-107109227-B | Ultraviolet light absorber | 光学转变公司 | 2021-05-04 | — | — | CN | disclosed |
| US-10619098-B2 | Ultraviolet light absorbers | TRANSITIONS OPTICAL, INC. (US) | 2020-04-14 | — | — | US | disclosed |
| EP-2970760-B1 | PHOTOCHROMIC ARTICLES THAT INCLUDE PHOTOCHROMIC-DICHROIC MATERIALS | TRANSITIONS OPTICAL INC (US) | 2019-06-26 | — | — | EP | disclosed |
| EP-3071550-B1 | METHOD OF PREPARING FUSED RING INDENO COMPOUNDS | TRANSITIONS OPTICAL INC (US) | 2019-03-13 | — | — | EP | disclosed |
| EP-3201292-B1 | ULTRAVIOLET LIGHT ABSORBERS | TRANSITIONS OPTICAL INC (US) | 2018-08-01 | — | — | EP | disclosed |
| EP-2303987-A1 | MESOGEN CONTAINING COMPOUNDS | TRANSITIONS OPTICAL, INC. (US) | 2011-04-06 | — | — | EP | disclosed |
| US-7910019-B2 | Mesogen containing compounds | TRANSITIONS OPTICAL, INC. (US) | 2011-03-22 | — | — | US | disclosed |
| US-20090326186-A1 | MESOGEN CONTAINING COMPOUNDS | TRANSITIONS OPTICAL, INC. (US) | 2009-12-31 | — | — | US | disclosed |
| US-20090323011-A1 | MESOGEN CONTAINING COMPOUNDS | TRANSITIONS OPTICAL, INC. (US) | 2009-12-31 | — | — | US | disclosed |
| WO-2009158483-A1 | MESOGEN CONTAINING COMPOUNDS | TRANSITIONS OPTICAL, INC. (US) | 2009-12-30 | — | — | WO | disclosed |
| US-7442418-B2 | Polymerizable liquid crystal compound, liquid crystal composition, optical anisotropic material and optical element | ASAHI GLASS COMPANY, LIMITED (JP) | 2008-10-28 | — | — | US | disclosed |
| US-20070104894-A1 | POLYMERIZABLE LIQUID CRYSTAL COMPOUND, LIQUID CRYSTAL COMPOSITION, OPTICAL ANISOTROPIC MATERIAL AND OPTICAL ELEMENT | ASAHI GLASS CO., LTD. (JP) | 2007-05-10 | — | — | US | disclosed |
| EP-0022183-B1 | DERIVATIVES OF CYCLOHEXYLBIPHENYL, PROCESS FOR THEIR PREPARATION, DIELECTRICS CONTAINING THEM, AND ELECTRON OPTICAL INDICATING ELEMENTS | MERCK PATENT GmbH (DE) | 1982-06-23 | — | — | EP | disclosed |
| US-4330426-A | Cyclohexylbiphenyls, their preparation and use in dielectrics and electrooptical display elements | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1982-05-18 | — | — | US | disclosed |
| EP-0022183-A2 | Derivatives of cyclohexylbiphenyl, process for their preparation, dielectrics containing them, and electron optical indicating elements | MERCK PATENT GmbH (DE) | 1981-01-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11739270-B2 | Polymerizable compound as well as liquid crystal composition and liquid crystal display device each including polymerizable compound | OCIAD2, PKN2, SKP1 | DRD2 271/4885CYP2C9 3955/4885MAPT 1064/4885 |
| US-10619098-B2 | Ultraviolet light absorbers | ERCC1, MCM4, ERCC4 | DRD2 1763/4885CYP2C9 484/4885MAPT 80/4885 |
| US-20090326186-A1 | MESOGEN CONTAINING COMPOUNDS | MYOC, BMP2, RARG | DRD2 883/4885CYP2C9 2891/4885MAPT 2243/4885 |
| US-20090323011-A1 | MESOGEN CONTAINING COMPOUNDS | MYOC, BMP2, RARG | DRD2 883/4885CYP2C9 2891/4885MAPT 2243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.